← Back to The Daily Signal
Mitochondria & Longevity

The Biggest NAD+ Supplement Trial Yet Raised NAD in the Blood and Did Nothing for Parkinson's

The pitch for NAD+ boosters is simple: NAD falls with age and disease, cells need it to make energy, so top it up. Parkinson's disease, where struggling mitochondria are part of the story, was always one of the most promising places to test that idea. A large Norwegian trial has now tested it properly.

Written by Sama Alabed · November 19, 2026

The short version

What the trial did

The trial randomized 410 people with early Parkinson's disease at 11 centers in Norway: 206 to nicotinamide riboside, often sold as NR, and 204 to placebo. The dose was 500 mg twice a day, 1,000 mg in total, for 52 weeks. The average participant was 65.6 years old.

The main measure was the MDS-UPDRS, the standard rating scale for Parkinson's, using parts I to III, which cover daily life experiences and movement. On this scale a higher score means more symptoms.

What it found

Over the year, scores rose by 2.45 points on nicotinamide riboside and fell by 0.27 points on placebo. After adjustment, the difference was 2.72 points in favor of placebo, with a confidence interval of 0.47 to 4.98. That is a small difference, and the honest reading is not that NR made Parkinson's worse but that it clearly did not make it better.

The biology explains part of it. Blood NAD levels rose on NR, by roughly 30 micromolar compared with placebo, so the supplement did what it is sold to do in the bloodstream. Brain imaging, though, found no difference in the NAD to ATP ratio, a marker of whether that extra NAD was reaching the brain's energy machinery.

UP

Blood NAD

Roughly 30 micromolar higher than placebo.

SAME

Brain NAD to ATP

No difference from placebo on imaging.

2.72

Points, favoring placebo

Adjusted difference on the MDS-UPDRS, where higher means more symptoms.

410 adults with early Parkinson's, 1,000 mg a day for 52 weeks, 11 centers in Norway.

Serious adverse events were reported in 8.3 percent of the NR group and 14.1 percent of the placebo group, a difference that was not statistically significant.

Why this result matters beyond Parkinson's

Many NAD supplements are marketed on the first half of this story: a measurable rise in NAD in the blood. This trial shows how little that rise can mean on its own. The blood number moved, and neither the tissue that mattered nor the outcome that mattered followed.

A large MRI scanner with its patient table in a hospital imaging room

An MRI scanner. The trial used brain imaging to check whether extra NAD reached the brain's energy chemistry.

Jan AinaliCC BY 3.0

Illustrative. Not the scanner or centre used in the trial.

The blood number moved, and neither the tissue that mattered nor the outcome that mattered followed.

A year long phase 3 trial of this size is a much stronger test than the small, short studies the NAD story has mostly rested on, and it came out negative.

Honest caveat

Participants were assessed while taking their usual Parkinson's medication, with no washout, which can blur small effects. The trial says nothing about other NAD precursors, other doses or healthy people. The study drug was supplied by ChromaDex, part of Niagen Bioscience, which sells nicotinamide riboside, and some investigators hold patents on NR licensed to that company. Those ties would, if anything, have favored a positive result.

What this means for you

If you take an NAD+ supplement hoping to protect your brain, this is the strongest evidence so far that a higher blood NAD number does not by itself translate into a benefit you would notice. It is not evidence of danger at these doses.

If you or someone you love has Parkinson's, this trial is a reason not to add nicotinamide riboside expecting it to slow the disease, and a reason to keep the conversation about supplements with the neurologist who knows the full treatment plan.

Primary sources

  1. JAMA, published online October 8, 2026: nicotinamide riboside in early Parkinson's disease, a randomized clinical trial, DOI 10.1001/jama.2026.18828
  2. News Medical, October 12, 2026, summary of the trial

Common questions

Did nicotinamide riboside make Parkinson's worse?

Symptom scores rose 2.72 points more on NR than on placebo after adjustment, a small difference. The safest reading is that NR did not help; the trial was not designed to prove harm, and serious adverse events were not higher on NR.

Did the supplement raise NAD?

Yes, in the blood, by roughly 30 micromolar compared with placebo. Brain imaging found no difference in the NAD to ATP ratio, so the rise did not appear to reach the brain's energy chemistry.

Does this apply to NMN or other NAD boosters?

Not directly. This trial tested nicotinamide riboside only. It does show that a rise in blood NAD is not proof of a benefit, which is relevant to how every NAD booster is marketed.

Continue readingMitochondria & LongevityBlood NAD+ Doesn't Decline With Age, the Best Measurement Yet FindsA team at Amsterdam UMC measured whole blood NAD+ across seven independent human cohorts using a mass spectrometry method built to survive real world lab noise, and found levels stable with age and unmoved by diet or exercise. Nicotinamide riboside supplementation still raised blood NAD+ as advertised. The premise underneath the entire NAD+, NMN and nicotinamide riboside category, that blood NAD+ is falling and needs restoring, describes a decline this method could not find. The authors' own conclusion is that blood NAD+ is not a useful aging biomarker.Read the storyRelated guideMitochondria HacksWhat actually supports cellular energy, which claims hold up, and where the evidence runs out.Read the guide
NAD+Nicotinamide RibosideParkinson'sMitochondriaClinical Trial

#NAD#NicotinamideRiboside#Parkinsons#Mitochondria#Longevity

Stay Curious.

Better health isn't found in a single article. It's built through curiosity, evidence, and small discoveries over time. Join thousands exploring longevity, gut health, recovery, nutrition, and the tools that truly make a difference.